"dcgi"

"SII has applied for emergency use authorisation to DCGI. The application will be reviewed by the expert committee and after that final call will be taken," a senior government official confirmed ANI.

This will be a multi-centre and randomised controlled study, which will include safety and immunogenicity study, Dr Reddy’s said in a statement.

Favipiravir is a broad spectrum antiviral agent and selectively inhibits RNA polymerase of influenza virus and prevents viral replication